These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 16266990)
1. Proteolysis of CCN1 by plasmin: functional implications. Pendurthi UR; Tran TT; Post M; Rao LV Cancer Res; 2005 Nov; 65(21):9705-11. PubMed ID: 16266990 [TBL] [Abstract][Full Text] [Related]
2. The matrix protein CCN1 (CYR61) promotes proliferation, migration and tube formation of endothelial progenitor cells. Yu Y; Gao Y; Wang H; Huang L; Qin J; Guo R; Song M; Yu S; Chen J; Cui B; Gao P Exp Cell Res; 2008 Oct; 314(17):3198-208. PubMed ID: 18755182 [TBL] [Abstract][Full Text] [Related]
3. The angiogenic factor CCN1 promotes adhesion and migration of circulating CD34+ progenitor cells: potential role in angiogenesis and endothelial regeneration. Grote K; Salguero G; Ballmaier M; Dangers M; Drexler H; Schieffer B Blood; 2007 Aug; 110(3):877-85. PubMed ID: 17429007 [TBL] [Abstract][Full Text] [Related]
4. CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3A-induced osteoblast differentiation of mesenchymal stem cells. Si W; Kang Q; Luu HH; Park JK; Luo Q; Song WX; Jiang W; Luo X; Li X; Yin H; Montag AG; Haydon RC; He TC Mol Cell Biol; 2006 Apr; 26(8):2955-64. PubMed ID: 16581771 [TBL] [Abstract][Full Text] [Related]
5. Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Gery S; Xie D; Yin D; Gabra H; Miller C; Wang H; Scott D; Yi WS; Popoviciu ML; Said JW; Koeffler HP Clin Cancer Res; 2005 Oct; 11(20):7243-54. PubMed ID: 16243794 [TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor (VEGF)-induced up-regulation of CCN1 in osteoblasts mediates proangiogenic activities in endothelial cells and promotes fracture healing. Athanasopoulos AN; Schneider D; Keiper T; Alt V; Pendurthi UR; Liegibel UM; Sommer U; Nawroth PP; Kasperk C; Chavakis T J Biol Chem; 2007 Sep; 282(37):26746-26753. PubMed ID: 17626014 [TBL] [Abstract][Full Text] [Related]
7. Expression of CCN1 (CYR61) in developing, normal, and diseased human kidney. Sawai K; Mukoyama M; Mori K; Kasahara M; Koshikawa M; Yokoi H; Yoshioka T; Ogawa Y; Sugawara A; Nishiyama H; Yamada S; Kuwahara T; Saleem MA; Shiota K; Ogawa O; Miyazato M; Kangawa K; Nakao K Am J Physiol Renal Physiol; 2007 Oct; 293(4):F1363-72. PubMed ID: 17699553 [TBL] [Abstract][Full Text] [Related]
8. A novel mechanism of plasmin-induced mitogenesis in fibroblasts. Mandal SK; Rao LV; Tran TT; Pendurthi UR J Thromb Haemost; 2005 Jan; 3(1):163-9. PubMed ID: 15634280 [TBL] [Abstract][Full Text] [Related]
9. Degradome products of the matricellular protein CCN1 as modulators of pathological angiogenesis in the retina. Choi J; Lin A; Shrier E; Lau LF; Grant MB; Chaqour B J Biol Chem; 2013 Aug; 288(32):23075-89. PubMed ID: 23798676 [TBL] [Abstract][Full Text] [Related]
10. Functional domains of CCN1 (Cyr61) regulate breast cancer progression. O'Kelly J; Chung A; Lemp N; Chumakova K; Yin D; Wang HJ; Said J; Gui D; Miller CW; Karlan BY; Koeffler HP Int J Oncol; 2008 Jul; 33(1):59-67. PubMed ID: 18575751 [TBL] [Abstract][Full Text] [Related]
11. Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors. Guillon-Munos A; Oikonomopoulou K; Michel N; Smith CR; Petit-Courty A; Canepa S; Reverdiau P; Heuzé-Vourc'h N; Diamandis EP; Courty Y J Biol Chem; 2011 Jul; 286(29):25505-18. PubMed ID: 21628462 [TBL] [Abstract][Full Text] [Related]
12. Tumor-derived Cyr61(CCN1) promotes stromal matrix metalloproteinase-1 production and protease-activated receptor 1-dependent migration of breast cancer cells. Nguyen N; Kuliopulos A; Graham RA; Covic L Cancer Res; 2006 Mar; 66(5):2658-65. PubMed ID: 16510585 [TBL] [Abstract][Full Text] [Related]
13. Identification of a novel integrin alphaMbeta2 binding site in CCN1 (CYR61), a matricellular protein expressed in healing wounds and atherosclerotic lesions. Schober JM; Lau LF; Ugarova TP; Lam SC J Biol Chem; 2003 Jul; 278(28):25808-15. PubMed ID: 12736251 [TBL] [Abstract][Full Text] [Related]
14. Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis. Bazzi ZA; Lanoue D; El-Youssef M; Romagnuolo R; Tubman J; Cavallo-Medved D; Porter LA; Boffa MB BMC Cancer; 2016 May; 16():328. PubMed ID: 27221823 [TBL] [Abstract][Full Text] [Related]
16. Functional properties and intracellular signaling of CCN1/Cyr61. Chen Y; Du XY J Cell Biochem; 2007 Apr; 100(6):1337-45. PubMed ID: 17171641 [TBL] [Abstract][Full Text] [Related]
17. Expression, purification, and functional testing of recombinant CYR61/CCN1. Schütze N; Kunzi-Rapp K; Wagemanns R; Nöth U; Jatzke S; Jakob F Protein Expr Purif; 2005 Jul; 42(1):219-25. PubMed ID: 15878827 [TBL] [Abstract][Full Text] [Related]
18. Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Sharma MR; Koltowski L; Ownbey RT; Tuszynski GP; Sharma MC Exp Mol Pathol; 2006 Oct; 81(2):146-56. PubMed ID: 16643892 [TBL] [Abstract][Full Text] [Related]